학술논문
Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients
Document Type
article
Author
K.A. Mapuskar; G. Vasquez Martinez; C.F. Pulliam; M.S. Petronek; E.J. Steinbach; V. Monga; M. Furqan; J.G. Jetton; D.P. Saunders; A. Pearce; S. Davidson; L. Pitre; N.E. Dunlap; R. Fairbanks; C.M. Lee; S.L. Mott; K.L. Bodeker; Huang Cl; J.M. Buatti; C.M. Anderson; R.A. Beardsley; J.T. Holmlund; D. Zepeda-Orozco; D.R. Spitz; B.G. Allen
Source
Redox Biology, Vol 60, Iss , Pp 102599- (2023)
Subject
Language
English
ISSN
2213-2317
Abstract
Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently with radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute and chronic kidney disease (AKD and CKD, respectively). We conducted a retrospective analysis of renal function and kidney injury-related plasma biomarkers in a subset of HNSCC subjects receiving hdCis-RT in a double-blinded, placebo-controlled clinical trial (NCT02508389) evaluating the superoxide dismutase mimetic, avasopasem manganese (AVA), an investigational new drug. We found that 90 mg AVA treatment prevented a significant reduction in estimated glomerular filtration rate (eGFR) three months as well as six and twelve months after treatment compared to 30 mg AVA and placebo. Moreover, AVA treatment may have allowed renal repair in the first 22 days following cisplatin treatment as evidenced by an increase in epithelial growth factor (EGF), known to aid in renal recovery. An upward trend was also observed in plasma iron homeostasis proteins including total iron (Fe-blood) and iron saturation (Fe-saturation) in the 90 mg AVA group versus placebo. These data support the hypothesis that treatment with 90 mg AVA mitigates cisplatin-induced CKD by inhibiting hdCis-induced renal changes and promoting renal recovery.